Metabolic Syndrome (MetS) is identified by dichotomous criteria thus masking MetS-related risk exists as a continuum. We assessed the association of a “MetS severity score” (MSs; courtesy Dr. M. DeBoer) with all-cause death in 774 T1D (age 40.2±11.7; DD 19.4±12.2 years; HbA1c 7.8±1.2%) over a 10.6±2.5 year follow-up. MSs was derived from WC, sBP, HDL and triglycerides (no glucose). Mean MSs was -0.5046±0.6717 (median -0.5820; IQR -0.9556 to -0.1529). MSs was stratified by quartiles. Compared to Q1, Q2-4 had a worse CV risk profile with increasing age, BMI, dBP, fasting glucose, HbA1c, total-, LDL- and nonHDL-Ch, uric acid and fibrinogen (p<0.0001). As expected, WC, sBP and triglycerides increased, while HDL decreased (p<0.0001). eGFR was steeply lower (p=0.006), ACR steeply higher (p=0.005). With MSs, rate of CV events (1.0, 4.6, 6.2 and 9.3%; p=0.003), eGFR <60 ml/min/1.73m2 (p=0.038), ACR strata (p=0.007) and retinopathy (p=0.003) increased. A total of 52 deaths occurred during the 8,184 person-years of follow-up (6.7%; 6.36x1000 person-years). Death rate increased with MSs: Q1 2.1%; Q2 5.7% (HR 3.10, 95% CI 0.99-9.75); Q3 5.7% (2.78, 0.88-8.73); Q4 13.5% (7.02, 2.45-20.12; p<0.0001). Adjusting for age (HR 1.08, 95% CI 1.06-1.11, p<0.0001) and sex (M, p=0.059), HRs vs. Q1 were: Q2 2.59 (95% CI 0.82-8.15); Q3 1.94 (0.61-6.12); Q4 4.24 (1.46-12.31; p=0.008). Adjusting for age (p<0.0001), sex (p=0.022), DD, BMI, HbA1c, LDL, CVD, retinopathy, eGFR (p=0.013) and ACR (p<0.001), HRs vs. Q1 were: Q2 3.36 (95% CI 1.05-10.76, p=0.041); Q3 2.21 (0.69-7.08); Q4 4.(1.39-11.75; p=0.01). In fully adjusted model for variables included in the equation, age, sex, eGFR and ACR were independent predictor of death, while HRs vs. Q1 (p=0.056) were: Q2 3.18 (95% CI 0.99-10.19, p=0.051); Q3 2.11 (0.66-6.75); Q4 3.87 (1.33-11.23; p=0.013). In individuals with T1DM, the highest MetS scores predict all-cause mortality indipendent of other CV risk factors and single components of MetS.


G. Penno: None. M. Garofolo: None. R. Giannarelli: None. F. Campi: None. D. Lucchesi: None. L. Giusti: None. V. Sancho-Bornez: None. A. Dardano: None. G. Daniele: None. R. Miccoli: None. S. Del Prato: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Servier, Sanofi, Takeda Pharmaceuticals U.S.A., Inc.. Research Support; Self; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals U.S.A., Inc.. Advisory Panel; Self; Janssen Biotech, Inc., Abbott.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at